Zosano Pharma (Zosano Pharma) Short-Term Debt & Capital Lease Obligation : $3.38 Mil (As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Zosano Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $3.38 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Zosano Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $2.66 Mil.

Zosano Pharma Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Zosano Pharma's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zosano Pharma Short-Term Debt & Capital Lease Obligation Chart

Zosano Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

6.69

2.33

5.71

6.97

5.43

Zosano Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															7.55	6.32	6.08	5.43	3.38

Zosano Pharma Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Zosano Pharma Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Zosano Pharma's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zosano Pharma (Zosano Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

34790 Ardentech Court, Fremont, CA, USA, 94555

Website

https://www.zosanopharma.com

Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.

Executives

Christine Matthews	officer: Chief Financial Officer	C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo	director, officer: Chief Executive Officer	C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman	officer: VP, Clinical Dev & Med Affairs	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang	director	C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse	director	3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis	officer: See Remarks	C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee	director	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos	director	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022